Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Mattel Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while Mattel Inc trades at $13.11 (market cap $3.90B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MAT | |
|---|---|---|
Market Cap | $4.49B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $22.16 |
52-Week Low | $20.06 | $13.05 |
Enterprise Value | $3.69B | $5.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Mattel (MAT) trades at $13.42, up 0.6% on the day, with a bearish technical signal but bullish oscillators like RSI suggesting potential oversold conditions. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results pending. Financially, it maintains solid profitability with a 9.27% net margin and attractive valuation ratios, including a P/E of 8.36. Recent news highlights brand expansions and a shareholder push for strategic alternatives.
The outlook is cautiously optimistic, supported by strong brand portfolio and analyst consensus, but risks include declining cash flows and competitive pressures. Investment opportunities lie in potential strategic moves and undervaluation, while key risks involve execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
